Therapeutic
Gritstone’s data “encouraging”, but are they enough?
Interim Phase II data from Gritstone bio’s study evaluating GRANITE in September 2024 are described as “encouraging” in a company statement.
IO Biotech: “promising” Phase II data for cancer candidate
In September 2024, IO Biotech announced “promising” data from its Phase II basket trial of IO102-IO103 in combination with Merck’s anti-PD-1
Investigational mRNA vaccine has promise in cancer trial
King’s College London shared in September 2024 that an mRNA cancer immunotherapy (mRNA-4359), targeted for patients with lung cancer,
Pancreatic cancer vaccine trial launches in Birmingham
Researchers at the University of Birmingham announced the launch of a trial to study the use of an mRNA cancer vaccine in the treatment of pancreatic
GSK’s herpes candidate fails to meet trial objective
GSK announced in September 2024 that it has completed the primary objective data analysis from the Phase II part of its TH HSV REC-003 trial.
Defence Therapeutics’ ARM-X anti-cancer vaccine effective
In June 2024, Defence Therapeutics announced that its second-generation ARM-X anti-cancer vaccine is “therapeutically effective” against pre-established ovarian cancer (ID8 model) in combination with an anti-PD-1 immune-checkpoint inhibitor. Using the Accum platform,...
Vaxxinity announces “beacon of hope” for Parkinson’s disease
In June 2024 Vaxxinity announced the publication of “groundbreaking exploratory data” from a Phase I clinical trial of UB-312 in patients with Parkinson’s disease (PD). UB-312 is an active immunotherapy medicine (AIM) designed to “slow or stop” the progression of...
Nykode’s mRNA-LNP platform has “significant advantages”
In June 2024 Nykode Therapeutics announced updates to its mRNA platform, highlighting the “significant advantages” of its APC-targeted neoantigen vaccine, delivered in an mRNA-lipid nanoparticle (LNP) format. A recent study demonstrates that the APC-targeted vaccine...
Sustained improvement in Moderna and Merck 3-year data
In June 2024 Moderna and Merck announced the first presentation of results from a planned analysis from the Phase IIb randomised KEYNOTE-942/mRNA-4157-P201 study. The study evaluates mRNA-4157 (V940) in combination with KEYTRUDA in patients with resected high-risk...
First enrolment in Transgene head and neck cancer trial
Transgene announced in June 2024 that the first patient has been enrolled in the Phase II part of a randomised Phase I/II clinical trial of TG4050 in the adjuvant treatment of head and neck cancer. Patient screening and enrolment are underway, with hopes of enrolling...
NHS patients access personalised cancer vaccine trials
NHS England announced in May 2024 that “thousands” of cancer patients across the country will get “fast-tracked” access to trials of personalised cancer vaccines through a new “matchmaking” service: the Cancer Vaccine Launch Pad (CVLP). The CVLP is platform intended...
CMV-vector vaccine a potential “shield” against cancer
Researchers at Oregon Health & Science University (OHSU) shared in May 2024 that their platform for cytomegalovirus-based vaccines has “promise” as a “shield” against cancer. Their paper in Science Advances presents the results of immunising rhesus macaques (RM)...
“Fierce” response with mRNA vaccine against glioblastoma
Researchers at the University of Florida shared in May 2024 that in a first in human trial of four adult patients, an mRNA cancer vaccine “quickly reprogrammed the immune system” against glioblastoma, the “most aggressive and lethal” brain tumour. Their results,...
UK begins trial of personalised mRNA against melanoma
In April 2024 we learnt of a trial of a personalised mRNA vaccine against the most dangerous form of skin cancer, melanoma. Recruitment for the University College London Hospital trial began in October 2023, and is expected to involve more than 60-70 patients at 8...
Gritstone shares “positive” data in ongoing GRANITE trial
In April 2024 Gritstone bio announced “positive” preliminary data from an ongoing Phase II portion of the Phase II/III study to evaluate GRANITE. GRANITE is Gritstone’s personalised neoantigen cancer vaccine and is being evaluated in front-line metastatic...
Geneos announces positive data in GT-30 clinical trial
In April 2024 Geneos Therapeutics announced the publication of “positive” safety, immunogenicity, and efficacy data from a full cohort of patients in the GT-30 clinical trial. The paper, in Nature Medicine, presents the 36-patient, single-arm, open-label, multi-centre...
Nykode announces therapeutic vaccine platform advances
In March 2024 Nykode Therapeutics announced “key updates” to the inverse vaccine platform with the potential to treat autoimmune diseases at a conference in the US. During the event, Nykode “demonstrated for the first time” a “significant effect” in a therapeutic...
DNA origami vaccines for precision immunotherapy
In March 2024 researchers at Wyss Institute announced the publication of research that indicates the possibility that DNA origami could serve as a platform for “controlling adjuvant spacing and co-delivering antigens in vaccines”. Their platform, DoriVac, enables the...
Parkinson’s: Vaxxinity shares “positive target engagement”
In March 2024 Vaxxinity announced “positive clinical data” from the UB-312 programme in Parkinson’s disease, presented by Dr Jean-Cosme Dodart, SVP of Research, at a conference. Vaxxinity identifies UB-312 as the “first active immunotherapy candidate” to show...
Despite “negative” results, Ultimovacs “committed” to UV1
In March 2024 Ultimovacs announced topline results from the Phase II clinical trial INITIUM, which evaluates the therapeutic cancer vaccine candidate UV1 as a first-line treatment in unresectable or metastatic malignant melanoma. While primary and secondary endpoints...
